Compare
REGENXBIO Inc. vs Ginkgo Bioworks Holdings, Inc. vs Adaptimmune Therapeutics PLC vs Beam Therapeutics Inc.
| Latest fiscal year | REGENXBIO Inc. RGNX | Ginkgo Bioworks Holdings, Inc. DNA | Adaptimmune Therapeutics PLC ADAPYLast annual report: year ended 2024-12-31 | Beam Therapeutics Inc. BEAM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 |
| Revenue | $170.44M | $170.16M | $178.03M | $139.74M |
| Revenue growth (YoY) | +104.5% | -25.1% | +195.3% | +120.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -94.6% | -185.3% | -38.6% | -274.6% |
| Net margin | -113.8% | -183.8% | -39.8% | -57.2% |
| Net income | -$193.88M | -$312.76M | -$70.81M | -$79.99M |
| EPS (Diluted) | -$3.76 | -$5.64 | -$0.05 | -$0.81 |
| Operating cash flow | -$123.96M | -$171.06M | -$73.21M | -$345.10M |
| Free cash flow | -$126.38M | -$178.72M | -$74.09M | -$360.05M |
| Cash & equivalents | $34.47M | $167.20M | $91.14M | $294.94M |
| Total assets | $453.03M | $1.12B | $245.96M | $1.48B |
| Total liabilities | $350.30M | $611.11M | $234.11M | $242.82M |
| Shareholders' equity | $102.73M | $508.59M | $11.85M | $1.24B |
| Return on year-end equity | -188.7% | -61.5% | -597.6% | -6.5% |
| Shares outstanding | 50.89M | 58.21M | 1.54B | 101.75M |
Revenue, most recent five fiscal years
| Fiscal year | REGENXBIO Inc. | Ginkgo Bioworks Holdings, Inc. | Adaptimmune Therapeutics PLC | Beam Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $170.44M Ended 2025-12-31 | $170.16M Ended 2025-12-31 | $178.03M Ended 2024-12-31 | $139.74M Ended 2025-12-31 |
| 1 year earlier | $83.33M Ended 2024-12-31 | $227.04M Ended 2024-12-31 | $60.28M Ended 2023-12-31 | $63.52M Ended 2024-12-31 |
| 2 years earlier | $90.24M Ended 2023-12-31 | $251.46M Ended 2023-12-31 | $27.15M Ended 2022-12-31 | $377.71M Ended 2023-12-31 |
| 3 years earlier | $112.72M Ended 2022-12-31 | $477.71M Ended 2022-12-31 | $6.15M Ended 2021-12-31 | $60.92M Ended 2022-12-31 |
| 4 years earlier | $470.35M Ended 2021-12-31 | $313.84M Ended 2021-12-31 | $3.96M Ended 2020-12-31 | $51.84M Ended 2021-12-31 |